Hepatocellular Carcinoma Showing Tumor Shrinkage Due to an Abscopal Effect

Overview

Journal Intern Med

Specialty General Medicine

Date 2023 May 17

PMID 37197962

Authors

Ryo Yano

Masashi Hirooka

Makoto Morita

Yuki Okazaki

Yoshiko Nakamura

Yusuke Imai

Takao Watanabe

Yohei Koizumi

Osamu Yoshida

Yoshio Tokumoto

Masanori Abe

Yoichi Hiasa

Affiliations

Soon will be listed here.

Abstract

We herein report a 63-year-old man who presented with left lower jaw pain and was diagnosed with hepatocellular carcinoma with bone metastases post-examination. All tumors grew after immunotherapy with atezolizumab and bevacizumab, and his jaw pain worsened. After palliative radiation therapy, however, the tumors shrank markedly, with no recurrence seen after stopping immunotherapy. To our knowledge, this is the first case in which a radiotherapy- and immunotherapy-mediated abscopal effect facilitated tumor shrinkage and immunotherapy discontinuation.

Citing Articles

Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma.

Tojjari A, Yu J, Saeed A Cancers (Basel). 2024; 16(5).

PMID: 38473415 PMC: 10930975. DOI: 10.3390/cancers16051058.

References

Lock M, Muinuddin A, Kocha W, Dinniwell R, Rodrigues G, DSouza D . Abscopal Effects: Case Report and Emerging Opportunities. Cureus. 2015; 7(10):e344. PMC: 4641721. DOI: 10.7759/cureus.344. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Rodriguez-Ruiz M, Rodriguez I, Barbes B, Mayorga L, Sanchez-Paulete A, Ponz-Sarvise M . Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy. 2017; 16(6):1246-1251. DOI: 10.1016/j.brachy.2017.06.012. View

Teng M, Ngiow S, Ribas A, Smyth M . Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015; 75(11):2139-45. PMC: 4452411. DOI: 10.1158/0008-5472.CAN-15-0255. View

Ngwa W, Irabor O, Schoenfeld J, Hesser J, Demaria S, Formenti S . Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018; 18(5):313-322. PMC: 5912991. DOI: 10.1038/nrc.2018.6. View

Yoo G, Ahn W, Kim S, Kang W, Choi C, Park H . Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study. Clin Mol Hepatol. 2020; 27(1):144-156. PMC: 7820196. DOI: 10.3350/cmh.2020.0095. View

Hiniker S, Reddy S, Maecker H, Subrahmanyam P, Rosenberg-Hasson Y, Swetter S . A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. Int J Radiat Oncol Biol Phys. 2016; 96(3):578-88. PMC: 5077166. DOI: 10.1016/j.ijrobp.2016.07.005. View

Yang J, Hainaut P, Gores G, Amadou A, Plymoth A, Roberts L . A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10):589-604. PMC: 6813818. DOI: 10.1038/s41575-019-0186-y. View

Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A . BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2021; 76(3):681-693. PMC: 8866082. DOI: 10.1016/j.jhep.2021.11.018. View

10.

Finn R, Qin S, Ikeda M, Galle P, Ducreux M, Kim T . Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20):1894-1905. DOI: 10.1056/NEJMoa1915745. View

11.

Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J . Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018; 11(1):104. PMC: 6097415. DOI: 10.1186/s13045-018-0647-8. View

12.

Postow M, Callahan M, Barker C, Yamada Y, Yuan J, Kitano S . Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(10):925-31. PMC: 3345206. DOI: 10.1056/NEJMoa1112824. View

13.

Ohmatsu K, Hashimoto Y, Kawanishi M, Ishii Y, Kono S, Kuribayashi S . Abscopal complete regression of hepatocellular carcinoma with multiple pleural metastases. Int Cancer Conf J. 2021; 10(1):54-58. PMC: 7797387. DOI: 10.1007/s13691-020-00446-y. View

14.

Hu Z, McArthur H, Ho A . The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer?. Curr Breast Cancer Rep. 2017; 9(1):45-51. PMC: 5346418. DOI: 10.1007/s12609-017-0234-y. View

15.

El-Serag H, Rudolph K . Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132(7):2557-76. DOI: 10.1053/j.gastro.2007.04.061. View

16.

Zhang Q, Lou Y, Bai X, Liang T . Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. World J Gastroenterol. 2018; 24(31):3500-3512. PMC: 6102497. DOI: 10.3748/wjg.v24.i31.3500. View

17.

Sangro B, Sarobe P, Hervas-Stubbs S, Melero I . Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18(8):525-543. PMC: 8042636. DOI: 10.1038/s41575-021-00438-0. View

18.

Wersall P, Blomgren H, Pisa P, Lax I, Kalkner K, Svedman C . Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006; 45(4):493-7. DOI: 10.1080/02841860600604611. View

19.

Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I . Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut. 1998; 43(4):575-7. PMC: 1727260. DOI: 10.1136/gut.43.4.575. View

20.

Mole R . Whole body irradiation; radiobiology or medicine?. Br J Radiol. 1953; 26(305):234-41. DOI: 10.1259/0007-1285-26-305-234. View